GLA - German Lymphoma Alliance

B-cell lymphoma is the most frequent lymphoid neoplasia accounting for one third of all lymphomas. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) is the current treatment standard, leading to high cure rates especially in younger patients. Although the 3-year event-free survival is about 60% even for elderly patients between 60-80 years old, the remainder of patients eventually relapse and the majority die of their disease. The German Non-Hodgkin's Lymphoma Study Group (DSHNHL) was founded in 1993 and has since conducted more than 25 national and international trials including more than 8000 patients in first line and salvage therapies. The DSHNHL is a network of haematooncologists, pathologists, radiologists, radiotherapists, nuclear physicians, biologists, geneticists and biometricians. All results of clinical trials performed by the DSHNHL were published in international journals and could lead a contribution to improve the treatment results.

Programme: NHL

LHA ID: 7RX4165T77-8

Funding codes:
  • Deutsche Krebshilfe
  • BMBF

Public web page: https://www.dshnhl.org

Human Diseases: Non-hodgkin lymphoma, B-cell lymphoma

Health Atlas - Local Data Hub/Leipzig PALs: Markus Löffler

Project Coordinators: No Project coordinators for this Project

Project created: 16th Apr 2019

Project Hierarchy
Powered by
(v.1.13.0-master)
Copyright © 2008 - 2021 The University of Manchester and HITS gGmbH
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig

By continuing to use this site you agree to the use of cookies